Skip to main content
PolicySpeak
← The ranking

Side by side

Compare organizations

Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.

Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

INR
INRAE

Academic / research · France

3
files engaged
of 583 tracked
3
positions filed
in those 583 files
declared FTE
self-declared
EP accreditations
as declared to the register

Files both filed on (2)

Medicinal products for human use · Evaluation of EU rules for users of genetic resources and the sharing of benefits arising from their utilization

Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.

What each said, in their own words

Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.

Medicinal products for human use

Bayer AG · filed 27 Apr 2021 · source

Creating an ambitious healthcare research ecosystem with pro-innovation policies and a fit for purpose research infrastructure is of utmost importance for Europe to remain competitive on the world stage and deliver breakthrough treatments for patients.

INRAE · filed 7 Nov 2023 · source

Introduction Inrae is the French Public Research Institute for Agriculture, Food and the Environment. It has had a leading position in the development of microbiome science and its application for human, animal and plant health.

Bayer AG · filed 7 Nov 2023 · source

Bayer is grateful for the opportunity to engage in the dialogue concerning the pharmaceutical legislation reform. Alongside our primary recommendations below, additional details can be found in the annex. Bayer has a 160-year legacy of European innovation and proudly maintains 11 Pharma R&D and production facilities throughout Europe.

Bayer AG · filed 7 Nov 2023 · source

Bayer is grateful for the opportunity to engage in the dialogue concerning the pharmaceutical legislation reform. Alongside our primary recommendations below, additional details can be found in the annex. Bayer has a 160-year legacy of European innovation and proudly maintains 11 Pharma R&D and production facilities throughout Europe.

Evaluation of EU rules for users of genetic resources and the sharing of benefits arising from their utilization

INRAE · filed 11 Feb 2026 · source

INRAE is a French public research institution which carries out, for the most part, basic research activities with no commercial objective in the field of agriculture, food and the environment, using public and private funding and national and international collaborations.

Filed in French · English published by the European Commission

Bayer AG · filed 11 Feb 2026 · source

Bayer's corporate mission Health for all - Hunger for none underscores the essential role that access to genetic resources plays in delivering innovations for health and food security. Bayer is fully committed to compliant access to genetic resources and supports the objectives of the Convention on Biological Diversity, the Nagoya Protocol, and Regulation (EU) 511/2014.

Take this comparison with you

2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.